Gregory Pendell, MD
Allergy & Immunology · Virginia Beach, VANPI 1831172121
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 850 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations.
Across 850 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- CSL Behring$2K
- GSK$1K
- Sanofi$1K
- Genentech USA, Inc.$1K
- plus $7K from 31 others
What the payments were for
- Consulting fees$830%
- Food & beverage$19,06799%
- Education$640%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 94 | $3,142 |
| Regeneron Healthcare Solutions, Inc. | 93 | $2,476 |
| CSL Behring | 133 | $2,364 |
| GSK | 84 | $1,452 |
| Sanofi | 51 | $1,309 |
| Genentech USA, Inc. | 53 | $1,039 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $1,007 |
| Grifols USA, LLC | 37 | $946 |
| Optinose US, Inc. | 40 | $658 |
| Amgen(2 entities) | 21 | $558 |
| Pharming Healthcare, Inc. | 21 | $512 |
| Pfizer | 27 | $512 |
| Novartis | 17 | $411 |
| Kaleo, Inc. | 21 | $400 |
| Shire North American Group Inc | 18 | $319 |
| Octapharma USA, Inc. | 5 | $273 |
| Regeneron | 2 | $245 |
| Teva Pharmaceuticals USA, Inc. | 12 | $229 |
| ADMA Biomanufacturing LLC | 8 | $176 |
| Biocryst US Sales Co., LLC | 9 | $175 |
| Blueprint Medicines Corporation | 9 | $172 |
| Ionis Pharmaceuticals, Inc. | 8 | $156 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $145 |
| Aimmune Therapeutics, Inc. | 5 | $103 |
| Alk-abello, Inc | 4 | $78 |
| Galderma Laboratories, L.p. | 3 | $56 |
| Bio Products Laboratory USA, Inc. | 3 | $51 |
| Incyte Corporation | 2 | $47 |
| Boehringer Ingelheim | 2 | $38 |
| Seqirus USA Inc | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $23 |
| Phadia US Inc. | 1 | $23 |
| AbbVie | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Circassia Inc. | 1 | $16 |
| Biocryst Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,214 in reported general payments places this provider in the 80th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 53 | $256,605 |
| XolairOmalizumab | 33 | $119,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $81,230 |
| Dupixent SyringeDupilumab | 14 | $52,180 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $26,170 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $23,404 |
| Spiriva RespimatTiotropium Bromide | 21 | $21,538 |
| Epinephrine | 85 | $18,130 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $12,145 |
| DuleraMometasone/Formoterol | 28 | $11,689 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $7,008 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $6,902 |
| Arnuity ElliptaFluticasone Furoate | 24 | $5,594 |
| Pulmicort FlexhalerBudesonide | 20 | $5,356 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $4,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,452 | $112,994170 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $3,142 | $40,90576 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $38 | $28,54634 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $18,13085 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $229 | $4,70311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 allergy & immunology providers in Virginia.
Other allergy & immunology in Virginia Beach
- Gary MossVirginia Beach$69K
- Robert RadinVirginia Beach$20K
- Marguerite LengkeekVirginia Beach$8K
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Andrew KimFredericksburg$104K
- Behnam DaghighLeesburg$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.